Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ABUS
ABUS logo

ABUS News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ABUS News

Arbutus Receives FDA Fast Track Designation for Imdusiran

Apr 15 2026Newsfilter

Arbutus Biopharma Reports Q4 Earnings with Strong Revenue Growth

Mar 23 2026seekingalpha

Arbutus and Take-Two Options Trading Activity

Mar 04 2026NASDAQ.COM

Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares

Mar 04 2026stocktwits

Midday Market Moves: Notable Stock Fluctuations

Mar 04 2026CNBC

Moderna Settles Patent Dispute with Arbutus and Genevant

Mar 04 2026seekingalpha

STAAR Surgical Reports Disappointing Q4 Results, Shares Plummet

Mar 04 2026Benzinga

Moderna Settles for $950 Million with Arbutus, Eyes Future Growth

Mar 04 2026Benzinga

ABUS Events

04/15 07:40
Arbutus Biopharma Receives FDA Fast Track Designation for Imdusiran in Chronic Hepatitis B Treatment
Arbutus Biopharma announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B.
03/04 16:20
U.S. Service Sector Expansion Boosts Stocks
Stocks ended the day higher after data showed the U.S. service economy expanded at the fastest pace since mid-2022 while a price index hit an almost one-year low, taking attention off geopolitical headlines for a session. The conflict in the Middle East has entered its fifth day and while there have been reports Iran has made indirect contact about potential talks, feeding some risk appetite, uncertainty around the durability of any de-escalation continues to drive positioning and the energy complex continues to influence the broader market's direction. Crude oil prices wavered near $75 per barrel in a volatile session.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applecontinued a week of new product launches, with the latest being thelaptopGooglesaid it isbrought against the company over its flagship AI product GeminiModernaentered into aworth up to $2.25B with a subsidiary of Roivant Sciencesand Arbutus BiopharmaRoss Storesreported a, raised its quarterly dividend and approved a new two-year $2.55B stock repurchase planFordreportedyear-over-year in February to 149,962 vehicles2. WALL STREET CALLS:BofA reinstated Teslaat Buy as the "Targetat Telsey Advisory and to Market Perform at BernsteinPiper Sandlerat NorthlandLegalZoomat BarclaysFirst Solarat GLJ Research on weak guidance3. AROUND THE WEB:AmazonPublisher Services, which helps websites run ad auctions, is exploring offering technology to help other apps and sites sell ads in AI chatbots, The Information saysOpenAI is developing an alternative to Microsoft'sGitHub, The Information reportsMetais testing a shopping research feature for its AI chatbot that will allow requests for product suggestions, Bloomberg saysThe White House is debating if it will allow Tencentto maintain stakes in popular video game groups, FT reportsDOJ investigating possible price fixing in fertilizer market, Bloomberg reports4. MOVERS:SCHMIDgained afterthe first specialized InfinityLine H+ systemEvolusadvanced afterand providing guidance for FY26Babcock & Wilcoxincreased afterand announcing it has received full notice to proceed on a $2.4B design-build agreement with Base ElectronIndie Semiconductorfell after filing to sell $150M ofGitLabclosed lower afterand authorizing a $400M share repurchase program5. EARNINGS/GUIDANCE:Abercrombie & Fitchreportedand provided guidance for Q1 and FY26Holleyreported, with EPS missing consensusDycomreported Q4 results, withon "strong fourth quarter performance"Bath & Body Worksreported, with EPS and revenue beating consensusBayerreportedand provided guidance for FY26INDEXES:The Dow rose 238.14, or 0.49%, to 48,739.41, the Nasdaq gained 290.79, or 1.29%, to 22,807.48, and the S&P 500 advanced 52.87, or 0.78%, to 6,869.50.

ABUS Monitor News

No data

No data

ABUS Earnings Analysis

No Data

No Data

People Also Watch